Skip to main content
NCBI home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1984 Apr;81(7):2232–2236. doi: 10.1073/pnas.81.7.2232

Antileukemic and immunosuppressive activity of 2-chloro-2'-deoxyadenosine.

D A Carson, D B Wasson, E Beutler
PMCID: PMC345472  PMID: 6585795

Abstract

The adenosine deaminase-resistant purine deoxynucleoside 2-chloro-2'-deoxyadenosine (CdA) is markedly toxic in vitro to nondividing and proliferating normal human lymphocytes and to many leukemia cell specimens. The CdA is also effective against mouse L1210 leukemia in vivo. The present investigations have examined the pharmacology, chemotherapeutic activity, and toxicity of CdA in nine patients with advanced hematologic malignancies refractory to conventional therapy. When administered by continuous intravenous infusion, the deoxyadenosine analog was well tolerated. As monitored by radioimmunoassay, plasma CdA levels rose gradually during the infusions. The CdA was not deaminated significantly. In all patients with leukemia, the CdA lowered the blast count by at least 50%. In one patient with a T-cell leukemia-lymphoma, and in another patient with chronic myelogenous leukemia in blast crisis, the CdA infusion eliminated all detectable blasts from the blood and bone marrow. In a patient with a diffuse lymphoma complicated by severe autoimmune hemolytic anemia, CdA treatment quickly terminated the hemolytic process. Bone marrow suppression represented the dose-limiting toxicity, and was related to plasma CdA levels, cumulative drug dosage, and the rapid release of CdA that accompanied tumor cell lysis.

Full text

PDF
2232

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brockman R. W., Cheng Y. C., Schabel F. M., Jr, Montgomery J. A. Metabolism and chemotherapeutic activity of 9-beta-D-arabinofuranosyl-2-fluoroadenine against murine leukemia L1210 and evidence for its phosphorylation by deoxycytidine kinase. Cancer Res. 1980 Oct;40(10):3610–3615. [PubMed] [Google Scholar]
  2. Carson D. A., Kaye J., Seegmiller J. E. Differential sensitivity of human leukemic T cell lines and B cell lines to growth inhibition by deoxyadenosine. J Immunol. 1978 Nov;121(5):1726–1731. [PubMed] [Google Scholar]
  3. Carson D. A., Kaye J., Seegmiller J. E. Lymphospecific toxicity in adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency: possible role of nucleoside kinase(s). Proc Natl Acad Sci U S A. 1977 Dec;74(12):5677–5681. doi: 10.1073/pnas.74.12.5677. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Carson D. A., Kaye J., Wasson D. B. The potential importance of soluble deoxynucleotidase activity in mediating deoxyadenosine toxicity in human lymphoblasts. J Immunol. 1981 Jan;126(1):348–352. [PubMed] [Google Scholar]
  5. Carson D. A., Wasson D. B., Kaye J., Ullman B., Martin D. W., Jr, Robins R. K., Montgomery J. A. Deoxycytidine kinase-mediated toxicity of deoxyadenosine analogs toward malignant human lymphoblasts in vitro and toward murine L1210 leukemia in vivo. Proc Natl Acad Sci U S A. 1980 Nov;77(11):6865–6869. doi: 10.1073/pnas.77.11.6865. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Carson D. A., Wasson D. B., Lakow E., Kamatani N. Possible metabolic basis for the different immunodeficient states associated with genetic deficiencies of adenosine deaminase and purine nucleoside phosphorylase. Proc Natl Acad Sci U S A. 1982 Jun;79(12):3848–3852. doi: 10.1073/pnas.79.12.3848. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Carson D. A., Wasson D. B., Taetle R., Yu A. Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes. Blood. 1983 Oct;62(4):737–743. [PubMed] [Google Scholar]
  8. Christensen L. F., Broom A. D., Robins M. J., Bloch A. Synthesis and biological activity of selected 2,6-disubstituted-(2-deoxy- -and- -D-erythro-pentofuranosyl)purines. J Med Chem. 1972 Jul;15(7):735–739. doi: 10.1021/jm00277a010. [DOI] [PubMed] [Google Scholar]
  9. Cohen A., Hirschhorn R., Horowitz S. D., Rubinstein A., Polmar S. H., Hong R., Martin D. W., Jr Deoxyadenosine triphosphate as a potentially toxic metabolite in adenosine deaminase deficiency. Proc Natl Acad Sci U S A. 1978 Jan;75(1):472–476. doi: 10.1073/pnas.75.1.472. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Coleman M. S., Donofrio J., Hutton J. J., Hahn L., Daoud A., Lampkin B., Dyminski J. Identification and quantitation of adenine deoxynucleotides in erythrocytes of a patient with adenosine deaminase deficiency and severe combined immunodeficiency. J Biol Chem. 1978 Mar 10;253(5):1619–1626. [PubMed] [Google Scholar]
  11. Dow L. W., Bell D. E., Poulakos L., Fridland A. Differences in metabolism and cytotoxicity between 9-beta-D arabinofuranosyladenine and 9-beta-D-arabinofuranosyl-2-fluoroadenine in human leukemic lymphoblasts. Cancer Res. 1980 May;40(5):1405–1410. [PubMed] [Google Scholar]
  12. Giblett E. R., Anderson J. E., Cohen F., Pollara B., Meuwissen H. J. Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity. Lancet. 1972 Nov 18;2(7786):1067–1069. doi: 10.1016/s0140-6736(72)92345-8. [DOI] [PubMed] [Google Scholar]
  13. Grever M. R., Siaw M. F., Jacob W. F., Neidhart J. A., Miser J. S., Coleman M. S., Hutton J. J., Balcerzak S. P. The biochemical and clinical consequences of 2'-deoxycoformycin in refractory lymphoproliferative malignancy. Blood. 1981 Mar;57(3):406–417. [PubMed] [Google Scholar]
  14. Hershfield M. S., Fetter J. E., Small W. C., Bagnara A. S., Williams S. R., Ullman B., Martin D. W., Jr, Wasson D. B., Carson D. A. Effects of mutational loss of adenosine kinase and deoxycytidine kinase on deoxyATP accumulation and deoxyadenosine toxicity in cultured CEM human T-lymphoblastoid cells. J Biol Chem. 1982 Jun 10;257(11):6380–6386. [PubMed] [Google Scholar]
  15. Koller C. A., Mitchell B. S., Grever M. R., Mejias E., Malspeis L., Metz E. N. Treatment of acute lymphoblastic leukemia with 2'-deoxycoformycin: clinical and biochemical consequences of adenosine deaminase inhibition. Cancer Treat Rep. 1979 Nov-Dec;63(11-12):1949–1952. [PubMed] [Google Scholar]
  16. Major P. P., Agarwal R. P., Kufe D. W. Clinical pharmacology of deoxycoformycin. Blood. 1981 Jul;58(1):91–96. [PubMed] [Google Scholar]
  17. Mitchell B. S., Koller C. A., Heyn R. Inhibition of adenosine deaminase activity results in cytotoxicity to T lymphoblasts in vivo. Blood. 1980 Sep;56(3):556–559. [PubMed] [Google Scholar]
  18. Mitchell B. S., Mejias E., Daddona P. E., Kelley W. N. Purinogenic immunodeficiency diseases: selective toxicity of deoxyribonucleosides for T cells. Proc Natl Acad Sci U S A. 1978 Oct;75(10):5011–5014. doi: 10.1073/pnas.75.10.5011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Montgomery J. A. Has the well gone dry? The First Cain Memorial Award Lecture. Cancer Res. 1982 Oct;42(10):3911–3917. [PubMed] [Google Scholar]
  20. Plunkett W., Chubb S., Alexander L., Montgomery J. A. Comparison of the toxicity and metabolism of 9-beta-D-arabinofuranosyl-2-fluoroadenine and 9-beta-D-arabinofuranosyladenine in human lymphoblastoid cells. Cancer Res. 1980 Jul;40(7):2349–2355. [PubMed] [Google Scholar]
  21. Poplack D. G., Sallan S. E., Rivera G., Holcenberg J., Murphy S. B., Blatt J., Lipton J. M., Venner P., Glaubiger D. L., Ungerleider R. Phase I study of 2'-deoxycoformycin in acute lymphoblastic leukemia. Cancer Res. 1981 Sep;41(9 Pt 1):3343–3346. [PubMed] [Google Scholar]
  22. Prentice H. G., Smyth J. F., Ganeshaguru K., Wonke B., Bradstock K. F., Janossy G., Goldstone A. H., Hoffbrand A. V. Remission induction with adenosine-deaminase inhibitor 2'-deoxycoformycin in Thy-lymphoblastic leukaemia. Lancet. 1980 Jul 26;2(8187):170–172. doi: 10.1016/s0140-6736(80)90060-4. [DOI] [PubMed] [Google Scholar]
  23. Siaw M. F., Mitchell B. S., Koller C. A., Coleman M. S., Hutton J. J. ATP depletion as a consequence of adenosine deaminase inhibition in man. Proc Natl Acad Sci U S A. 1980 Oct;77(10):6157–6161. doi: 10.1073/pnas.77.10.6157. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES